Literature DB >> 19878229

New era for personalized medicine: the diagnosis and management of age-related macular degeneration.

Paul N Baird1, Gregory S Hageman, Robyn H Guymer.   

Abstract

It can be argued that age-related macular degeneration is one of the best characterized complex trait diseases. Extensive information related to genetic and environmental risk factors exists, and a number of different biological pathways are strongly implicated in its aetiology. Along with recent improvements in high throughput and relatively inexpensive genetic technologies, we are now in a position to consider developing a presymptomatic, personalized approach towards the assessment, management and treatment of this disease. We explore the applicability and challenges of this approach if it is to become commonplace for guiding treatment decisions for individuals with pre-existing disease or for those at high risk of developing it.

Entities:  

Mesh:

Year:  2009        PMID: 19878229      PMCID: PMC4853908          DOI: 10.1111/j.1442-9071.2009.02136.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  64 in total

1.  Susceptibility genes for age-related maculopathy on chromosome 10q26.

Authors:  Johanna Jakobsdottir; Yvette P Conley; Daniel E Weeks; Tammy S Mah; Robert E Ferrell; Michael B Gorin
Journal:  Am J Hum Genet       Date:  2005-07-26       Impact factor: 11.025

2.  1000 Genomes Project promises closer look at variation in human genome.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

Review 3.  The current landscape for direct-to-consumer genetic testing: legal, ethical, and policy issues.

Authors:  Stuart Hogarth; Gail Javitt; David Melzer
Journal:  Annu Rev Genomics Hum Genet       Date:  2008       Impact factor: 8.929

4.  CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration.

Authors:  Mingyao Li; Pelin Atmaca-Sonmez; Mohammad Othman; Kari E H Branham; Ritu Khanna; Michael S Wade; Yun Li; Liming Liang; Sepideh Zareparsi; Anand Swaroop; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2006-08-27       Impact factor: 38.330

5.  A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration.

Authors:  Anne E Hughes; Nick Orr; Hossein Esfandiary; Martha Diaz-Torres; Timothy Goodship; Usha Chakravarthy
Journal:  Nat Genet       Date:  2006-09-24       Impact factor: 38.330

6.  Complement factor H polymorphism and age-related macular degeneration.

Authors:  Albert O Edwards; Robert Ritter; Kenneth J Abel; Alisa Manning; Carolien Panhuysen; Lindsay A Farrer
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

7.  Complement factor H variant increases the risk of age-related macular degeneration.

Authors:  Jonathan L Haines; Michael A Hauser; Silke Schmidt; William K Scott; Lana M Olson; Paul Gallins; Kylee L Spencer; Shu Ying Kwan; Maher Noureddine; John R Gilbert; Nathalie Schnetz-Boutaud; Anita Agarwal; Eric A Postel; Margaret A Pericak-Vance
Journal:  Science       Date:  2005-03-10       Impact factor: 47.728

8.  Complement factor H polymorphisms in Japanese population with age-related macular degeneration.

Authors:  Haru Okamoto; Shinsuke Umeda; Minoru Obazawa; Masayoshi Minami; Toru Noda; Atsushi Mizota; Miki Honda; Minoru Tanaka; Risa Koyama; Ikue Takagi; Yoshihiro Sakamoto; Yoshihiro Saito; Yozo Miyake; Takeshi Iwata
Journal:  Mol Vis       Date:  2006-03-06       Impact factor: 2.367

9.  Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study.

Authors:  Sarah Ennis; Catherine Jomary; Robert Mullins; Angela Cree; Xiaoli Chen; Alex Macleod; Stephen Jones; Andrew Collins; Edwin Stone; Andrew Lotery
Journal:  Lancet       Date:  2008-10-06       Impact factor: 79.321

10.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.

Authors:  Milam A Brantley; Amy M Fang; Jennifer M King; Asheesh Tewari; Steven M Kymes; Alan Shiels
Journal:  Ophthalmology       Date:  2007-12       Impact factor: 12.079

View more
  8 in total

Review 1.  Genetic diversity and medicinal drug response in eye care.

Authors:  Barkur S Shastry
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-05       Impact factor: 3.117

2.  Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study.

Authors:  Salomon-Yves Cohen; Eric H Souied; Michel Weber; Gérard Dupeyron; Gérard de Pouvourville; Michel Lievre; Anne Ponthieux
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-11-06       Impact factor: 3.117

3.  Prevalence of age-related macular degeneration in an elderly UK Caucasian population-The Bridlington Eye Assessment Project: a cross-sectional study.

Authors:  C Wilde; A Poostchi; R L Mehta; H K MacNab; J G Hillman; S A Vernon; W M Amoaku
Journal:  Eye (Lond)       Date:  2017-03-10       Impact factor: 3.775

4.  Fundus autofluorescence and spectral-domain optical coherence tomography characteristics in a rapidly progressing form of geographic atrophy.

Authors:  Monika Fleckenstein; Steffen Schmitz-Valckenberg; Christine Martens; Sebastian Kosanetzky; Christian K Brinkmann; Gregory S Hageman; Frank G Holz
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-01       Impact factor: 4.799

5.  Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics.

Authors:  Michael Feehan; John Hartman; Richard Durante; Margaux A Morrison; Joan W Miller; Ivana K Kim; Margaret M DeAngelis
Journal:  BMC Med Genet       Date:  2011-06-17       Impact factor: 2.103

Review 6.  Update of genetic susceptibility in patients with Kawasaki disease.

Authors:  Kyung Lim Yoon
Journal:  Korean J Pediatr       Date:  2015-03-20

Review 7.  Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development.

Authors:  Aniruddha Agarwal; William R Rhoades; Mostafa Hanout; Mohamed Kamel Soliman; Salman Sarwar; Mohammad Ali Sadiq; Yasir Jamal Sepah; Diana V Do; Quan Dong Nguyen
Journal:  Clin Ophthalmol       Date:  2015-06-05

8.  Personalized Medicine in Ophthalmology: From Pharmacogenetic Biomarkers to Therapeutic and Dosage Optimization.

Authors:  Frank S Ong; Jane Z Kuo; Wei-Chi Wu; Ching-Yu Cheng; Wendell-Lamar B Blackwell; Brian L Taylor; Wayne W Grody; Jerome I Rotter; Chi-Chun Lai; Tien Y Wong
Journal:  J Pers Med       Date:  2013
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.